Abstract
Driver mutations in the epidermal growth factor receptor (EGFR) gene represent a positive prognostic marker in non-small cell lung cancer (NSCLC). Tyrosine kinase inhibitors significantly improved quality of life and survival in these patients.
An EGFR exon 20 insertion represents a resistant exception. Amivantamab is a bispecific monoclonal antibody that has shown significant efficacy in EGFR ins20 positive NSCLC and is available in the Czech Republic.
Many clinical trials are currently underway.